Osocimab for VTE Prevention After TKA, Changes in FDA Approval and Regulation of Pharmaceuticals, Neuropsych Testing of Older Clinicians Prior to Recredentialing, and more episode artwork

EPISODE · Jan 14, 2020 · 12 MIN

Osocimab for VTE Prevention After TKA, Changes in FDA Approval and Regulation of Pharmaceuticals, Neuropsych Testing of Older Clinicians Prior to Recredentialing, and more

from JAMA Editors' Summary

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the January 14, 2020 issue

Episode metadata supplied by the publisher feed · Published Jan 14, 2020

Embed this episode

Ready to play

Osocimab for VTE Prevention After TKA, Changes in FDA Approval and Regulation of Pharmaceuticals, Neuropsych Testing of Older Clinicians Prior to Recredentialing, and more

0:00 12:18

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JAMA Editors' Summary?

This episode is 12 minutes long.

When was this JAMA Editors' Summary episode published?

This episode was published on January 14, 2020.

Can I download this JAMA Editors' Summary episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!